120 related articles for article (PubMed ID: 30132064)
1. New treatments in Alzheimer's disease.
Pickrell WO; Robertson NP
J Neurol; 2018 Sep; 265(9):2162-2163. PubMed ID: 30132064
[No Abstract] [Full Text] [Related]
2. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
3. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
4. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
5. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
[TBL] [Abstract][Full Text] [Related]
6. Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial.
Tajadini H; Saifadini R; Choopani R; Mehrabani M; Kamalinejad M; Haghdoost AA
Complement Ther Med; 2015 Dec; 23(6):767-72. PubMed ID: 26645514
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
[TBL] [Abstract][Full Text] [Related]
9. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.
Akhondzadeh S; Noroozian M; Mohammadi M; Ohadinia S; Jamshidi AH; Khani M
J Clin Pharm Ther; 2003 Feb; 28(1):53-9. PubMed ID: 12605619
[TBL] [Abstract][Full Text] [Related]
10. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
Soininen H; Solomon A; Visser PJ; Hendrix SB; Blennow K; Kivipelto M; Hartmann T;
Lancet Neurol; 2017 Dec; 16(12):965-975. PubMed ID: 29097166
[TBL] [Abstract][Full Text] [Related]
11. Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial.
Barak Y; Levine J; Glasman A; Elizur A; Belmaker RH
Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):729-35. PubMed ID: 8843494
[TBL] [Abstract][Full Text] [Related]
12. Double blind study of lecithin in patients with Alzheimer's disease.
Fisman M; Merskey H; Helmes E; McCready J; Colhoun EH; Rylett BJ
Can J Psychiatry; 1981 Oct; 26(6):426-8. PubMed ID: 7028239
[No Abstract] [Full Text] [Related]
13. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
15. Early results from double-blind, placebo controlled trial of high dose phosphatidylcholine in Alzheimer's disease.
Levy R; Little A; Chuaqui P; Reith M
Lancet; 1983 Apr; 1(8331):987-8. PubMed ID: 6132292
[No Abstract] [Full Text] [Related]
16. Acetyl-carnitine and Alzheimer's disease.
Bowman BA
Nutr Rev; 1992 May; 50(5):142-4. PubMed ID: 1630720
[No Abstract] [Full Text] [Related]
17. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin for patients with Alzheimer's disease psychosis.
Schneider LS
Lancet Neurol; 2018 Mar; 17(3):194-195. PubMed ID: 29452674
[No Abstract] [Full Text] [Related]
19. Methylphenidate and Apathy in Alzheimer's Disease: Is Sleep Apnea a Confounding Effect?
Kolla BP; Mansukhani MP
Am J Psychiatry; 2018 Aug; 175(8):792. PubMed ID: 30064252
[No Abstract] [Full Text] [Related]
20. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease.
Flicker C; Ferris SH; Kalkstein D; Serby M
Am J Psychiatry; 1994 Jan; 151(1):126-9. PubMed ID: 8267111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
